Siemens Healthineers: ARPA-H Grant Fuels Flash Therapy Push as Diagnostics Sale Looms

Siemens Healthineers secures $60M ARPA-H grant for FLASH radiation tech, but stock nears 52-week low amid restructuring, tariffs, and delayed spin-off.

The US Advanced Research Projects Agency for Health (ARPA-H) is injecting up to $60 million into Siemens Healthineers’ oncology arm Varian, backing a next-generation radiation technology that could reshape cancer treatment. The funding marks the first ARPA-H award in the radio-oncology space, and Siemens Healthineers is chipping in another $23 million of its own, bringing the total commitment to roughly $83 million over five years.

The project centers on Photon-FLASH-RT, a technique that delivers radiation doses more than 100 times faster than conventional methods. The premise is straightforward: by compressing treatment into ultra-rapid bursts, healthy tissue absorbs less damage, potentially opening up tumors where side effects have historically limited therapy. While earlier FLASH research has focused on proton and electron beams, Siemens Healthineers is betting on standard linear accelerators — a deliberate choice given that photon beams remain the dominant modality in radiation oncology worldwide.

The news arrives at a difficult moment for the stock. Shares are trading at €35.05, barely above the 52-week low of €33.80, and have shed more than 21% since the start of the year. The relative strength index has sunk to 28.6, deep in oversold territory, reflecting the breadth of headwinds battering the company.

Behind the scenes, management is weighing a radical restructuring. The diagnostics unit, which has long dragged on group margins, is being shopped to private equity buyers in a deal that could fetch around €6 billion. First-quarter revenues in the division slipped roughly 3%, hurt particularly by weak demand in China. A sale would serve a dual purpose: offloading the weakest-performing segment while chipping away at a debt pile of approximately €14 billion. No final decision has been made, and the company could still opt to keep the business under its own roof.

The macro environment is compounding the pressure. New US tariffs are expected to weigh on adjusted EBIT by around €400 million this year, while unfavorable currency moves could add another €200 million to €250 million in costs. At home, Germany’s planned healthcare reform aims to squeeze €20 billion in savings by 2027, with more than 40% of that falling on hospitals — a dynamic that is visibly dampening investment appetite for medical equipment.

Meanwhile, the long-awaited separation from parent Siemens is moving more slowly than many had hoped. The spin-off vote is now slated for the annual general meeting in February 2027, rather than an extraordinary shareholder gathering in the first half of 2026 as some investors anticipated. Under the plan, Siemens will transfer 30% of its stake directly to its own shareholders, effectively ceding control. The delay pushes the final decision back by nearly a year.

Analysts remain surprisingly bullish despite the carnage. The consensus price target sits at roughly €54, implying more than 50% upside from current levels. The logic: a fully independent Siemens Healthineers with a broader free float should attract a wider investor base. JPMorgan and Barclays both maintain “Overweight” ratings, even as the stock trades nearly 20% below its 200-day moving average.

The next major test comes on May 7, when Siemens Healthineers reports second-quarter results for fiscal 2026 at 07:00 CEST, followed by a press conference half an hour later. Management is sticking to full-year revenue growth guidance of 5% to 6%, a target that looks increasingly ambitious given the tariff headwinds, currency drag, and sluggish Chinese demand. Analysts expect full-year earnings per share of €2.29 and a dividend of €1.01. The market will be listening closely for any official acknowledgment of the diagnostics sale talks — and whether the Varian integration and innovation projects like the ARPA-H collaboration can stabilize operating margins as the broader storm rages on.